King's College London researchers report that a drug called KCL-286 helped repair DNA breaks and reduce inflammation in mice with an Alzheimer's-like disease. The work is preclinical, meaning it has been tested in animals and not yet in people with Alzheimer's, but the researchers see the drug as a possible disease-modifying therapy rather than one that only eases symptoms.
Most Alzheimer's drug development has centered on two proteins, amyloid-beta, which collects into sticky deposits between nerve cells, and tau, which forms tangles inside them. Medications that clear amyloid-beta have shown modest but measurable clinical benefits, yet they do not fully address the many biological processes involved in the disease. DNA damage and inflammation are increasingly studied as other contributors, and both can appear early in the disease process.
KCL-286 is a small molecule taken by mouth, which may be more convenient than treatments given by injection or infusion. It works by activating a protein in the retinoic acid pathway, a system linked to how the body processes vitamin A. Earlier research had found that disruptions in this pathway were associated with amyloid-beta deposits in the brains of rats, which is part of why the team considered it relevant to Alzheimer's.
The drug had previously shown it could promote repair of DNA double-strand breaks in research on neuropathic pain. That led the team to ask whether the same mechanism could address DNA damage in Alzheimer's. Because earlier work by the same group had identified molecular pathways shared by acute spinal cord injury and Alzheimer's, they also suspected a drug developed for spinal cord injury might influence Alzheimer's-related changes in neurons.
A notable advantage is that KCL-286 has already completed Phase 1 human safety and tolerability trials. Professor Jonathan Corcoran of King's College London said this could dramatically cut the traditional multi-year timeline for new drug development. Its effectiveness against Alzheimer's in humans has not been established, and the researchers say further studies and clinical trials will be needed to learn whether it can safely slow progression or improve outcomes.